Breast Implant-Associated Lymphoma: Symptoms, Tests and What Patients Should Do

Breast implant-associated anaplastic large-cell lymphoma, commonly called BIA-ALCL, is a rare type of non-Hodgkin lymphoma associated predominantly with textured-surface breast implants. Although the condition is uncommon, understanding its warning signs and diagnostic pathway can help patients seek appropriate medical advice without unnecessary delay.

In Short

• BIA-ALCL is a rare lymphoma, not breast cancer, that usually develops in fluid or scar tissue around a breast implant.
• New or persistent swelling, fluid around an implant, asymmetry, pain, a mass or enlarged lymph nodes should be assessed by a qualified healthcare professional.
• Ultrasound and, when needed, testing of peri-implant fluid or tissue are used to investigate suspected cases.
• For people without symptoms, the FDA does not recommend routine implant removal solely because of BIA-ALCL concerns.

BIA-ALCL is not breast cancer. It is a cancer of immune-system cells called T lymphocytes and most often develops in the fluid or scar capsule surrounding an implant rather than in the breast tissue itself. The condition can usually be investigated with a clinical examination, ultrasound and, when indicated, laboratory analysis of fluid or tissue.

This article explains the symptoms, tests, treatment principles and practical next steps for patients with breast implants, including international patients considering assessment or treatment in Turkey. Individual diagnosis and treatment decisions must always be made by a qualified physician and an appropriate multidisciplinary team.

What Is Breast Implant-Associated Lymphoma?

BIA-ALCL is a rare T-cell non-Hodgkin lymphoma linked mainly to textured breast implant surfaces. It is generally found in the peri-implant fluid or in the fibrous scar capsule that naturally forms around an implant. In some cases, it can form a mass involving the capsule or nearby tissues.

The exact risk is difficult to quantify. Estimates vary according to the implant surface, individual product, available registries and the design of each study. Current evidence indicates that the risk is higher with textured implants than with smooth implants, but the level of risk differs substantially between textured products. Implant filling material, such as silicone or saline, has not been established as a risk factor.

Having a breast implant does not mean that a patient will develop BIA-ALCL. Most changes around implants have other explanations, including infection, ordinary fluid accumulation, capsular contracture, implant rupture or other benign conditions. However, persistent or late-onset symptoms should be assessed by a qualified healthcare professional.

Symptoms of BIA-ALCL

Symptoms often occur years after breast implant surgery rather than immediately after implantation. The most common presentation is a delayed, persistent swelling caused by fluid collecting around the implant. This is sometimes called a late seroma.

Possible warning signs include:

• New or persistent swelling of one breast
• A fluid collection around the implant
• A breast or armpit mass
• New breast asymmetry
• Pain or tenderness
• Hardening or tightening around the implant
• Changes in breast shape or appearance
• Enlarged lymph nodes, particularly in the armpit

These symptoms do not confirm lymphoma. They may result from several different implant-related or breast-related conditions. The important point is that a new, persistent or progressive change should not be ignored or self-diagnosed.

Patients should contact a qualified plastic surgeon, breast specialist or physician promptly if they notice these changes.

Who Should Seek Assessment?

Any patient with breast implants who develops a new or persistent peri-implant change should arrange a medical evaluation. Assessment is especially important when symptoms appear several years after the original operation, when one breast becomes suddenly larger, or when a mass or enlarged lymph node is present.

Patients do not need to wait until they have several symptoms. A single persistent change, such as unexplained swelling or asymmetry, is a reasonable reason to request an examination.

For people without symptoms, routine implant removal is not recommended by the U.S. Food and Drug Administration solely because of concerns about BIA-ALCL. There is also no recommended imaging test specifically designed to screen asymptomatic patients for BIA-ALCL. Patients should remain aware of possible symptoms, attend routine clinical follow-up when advised and keep records of their implant manufacturer and model.

How Is BIA-ALCL Diagnosed?

Diagnosis usually begins with a medical history and physical examination. The doctor may ask when the implant was placed, which implant type was used, whether it has a textured surface and when the symptoms began. Previous operation reports, implant cards and manufacturer information can be useful.

Ultrasound

Ultrasound is generally the preferred first imaging test when BIA-ALCL is suspected. It can help identify fluid around the implant, a capsular abnormality, a mass or enlarged lymph nodes. Ultrasound does not by itself diagnose lymphoma, but it helps determine whether fluid or tissue should be sampled.

Fluid aspiration

If fluid is found around the implant, an ultrasound-guided aspiration may be performed. A sample of the peri-implant fluid should be sent for appropriate laboratory analysis, including cytology and immunohistochemical testing.

Testing commonly includes CD30 immunohistochemistry, which is an important part of the assessment for BIA-ALCL. Additional studies, including ALK and other laboratory investigations, may be requested according to the clinical situation and the pathologist’s assessment. Adequate fluid collection and correct handling of the sample are important, so testing should be coordinated by experienced clinicians and laboratories.

Biopsy of a mass or capsule

If imaging identifies a mass, the mass may require an image-guided or surgical biopsy. The scar capsule may also need pathological examination, particularly when surgery is performed or when the findings suggest involvement of the capsule.

Further staging investigations

If BIA-ALCL is confirmed, the specialist team may recommend additional investigations to assess the extent of disease. These can include further imaging such as PET-CT, depending on the findings and the patient’s individual situation. The purpose of staging is to guide treatment planning rather than to screen people who have no symptoms.

What Patients Should Do Before Their Appointment

Preparing relevant information can make the assessment more efficient. Patients should try to collect:

• The date and type of their breast implant operation
• The implant manufacturer, model and surface type, if available
• Implant cards, operative reports or previous medical records
• Details of previous breast surgery or implant replacement
• A description of when symptoms began and how they have changed
• Any previous imaging reports or laboratory results

International patients travelling to Turkey for assessment should send available records to the clinic or hospital in advance when possible. These may include translated reports, previous ultrasound images and implant documentation. However, remote review cannot replace an in-person examination, imaging and appropriate sampling when clinically indicated.

Patients should not attempt to drain swelling themselves or delay evaluation because they are uncertain whether their implant is textured. A doctor can determine which investigations are appropriate.

Treatment After a Confirmed Diagnosis

Confirmed BIA-ALCL requires specialist multidisciplinary management. The team may include a plastic surgeon, oncologist, radiologist, pathologist and other relevant specialists. Treatment depends on whether the disease is limited to fluid around the implant, involves the capsule or forms a mass, as well as whether lymph nodes or other areas are affected.

FDA guidance states that confirmed cases should undergo removal of the implant and the surrounding scar capsule. This is more extensive than simply removing the implant alone because the capsule may contain abnormal cells. The operation and any need for additional treatment should be planned by specialists familiar with BIA-ALCL.

Depending on disease extent, additional oncologic treatment may be considered. This could involve further surgery or other cancer treatments determined by the specialist team. Patients should receive an individualized plan based on pathology and staging results rather than relying on general online information.

Recovery and Follow-Up

Recovery depends on the extent of surgery, the condition of the capsule and whether additional treatment is required. Before surgery, the medical team should explain the planned procedure, possible reconstructive choices and the likely follow-up pathway.

After treatment, follow-up appointments are important. Patients may need clinical examinations, review of pathology results and imaging or oncology follow-up according to their diagnosis. The exact surveillance plan is individualized and should be provided by the treating team.

Patients should report new swelling, a mass, pain, changes in breast shape or enlarged lymph nodes during follow-up. Keeping copies of pathology reports, operation notes and implant details can be helpful if care takes place in more than one country.

Risks and Important Uncertainties

The principal risk factor currently recognized is the presence of a textured implant, but risk differs among products and cannot be summarized by one universally applicable figure. The evidence base continues to develop, and epidemiological estimates are affected by differences in product identification, reporting systems and study methods.

It is also important to distinguish BIA-ALCL from other implant-related problems. Implant rupture, capsular contracture, infection and benign seroma can cause similar symptoms. This is why a clinical assessment and appropriate laboratory testing are necessary.

Preventive implant removal is not routinely recommended for people without symptoms solely because of BIA-ALCL concerns. In selected situations, a patient and physician may discuss implant replacement or removal for other medical or personal reasons, but this decision should be individualized after considering the benefits, risks and alternatives.

When Should You Contact Estexper Clinic?

Patients considering evaluation in Turkey may contact Estexper Clinic if they have persistent swelling, asymmetry, pain, hardening, a breast or armpit mass, or another unexplained change around a breast implant. The clinic team can help organize an appropriate consultation and advise what existing records may be useful to provide.

A medical consultation should determine whether ultrasound, fluid aspiration, biopsy or referral to additional specialists is appropriate. No diagnosis should be made from symptoms alone, and treatment suitability must be assessed by a qualified physician after reviewing the patient’s history, examination and test results.

Frequently Asked Questions

Is BIA-ALCL the same as breast cancer?

No. BIA-ALCL is a rare T-cell non-Hodgkin lymphoma. It most often develops in the scar capsule or fluid around an implant rather than in breast tissue.

Are smooth implants completely risk-free?

No implant-related risk can be summarized as completely risk-free. Current evidence indicates that BIA-ALCL is associated predominantly with textured implants and that risk is higher with textured than smooth surfaces. Patients should discuss their individual implant history with a qualified physician.

Should I remove my implants if I have no symptoms?

Routine removal is not recommended by the FDA solely to prevent BIA-ALCL in people without symptoms. Patients should remain informed, maintain appropriate follow-up and seek medical advice if new changes develop.

Can an ultrasound diagnose BIA-ALCL?

Ultrasound is usually the preferred initial test, but it does not confirm the diagnosis on its own. If fluid or a mass is found, laboratory analysis of aspirated fluid or a biopsy may be required.

Can BIA-ALCL be treated?

Confirmed cases require specialist management. Treatment commonly involves removal of the implant and surrounding capsule, while additional treatment depends on the extent of disease and the multidisciplinary team’s recommendations.

For information about treatment planning and individual assessment, visit our Breast Augmentation page.

Explore our Plastic Surgery services in Turkey for an overview of treatment options and individual assessment.

Medical References

1. Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) — U.S. Food and Drug Administration.
2. Best Practices Guideline for the Pathologic Diagnosis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma — Journal of Clinical Oncology; FDA-convened expert pathology group.
3. American Association of Plastic Surgeons Consensus on Breast Implant–Associated Anaplastic Large-Cell Lymphoma — American Association of Plastic Surgeons.
4. Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL — Breast; multidisciplinary expert panel.
5. 2024 EURAPS Expert Consensus on breast implant associated-anaplastic large cell lymphoma — European Association of Plastic Surgeons.